| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/25/2002 | US20020098583 Composition for use in the treatment of cell cycle defects, autoimmune diseases, aging, cancer, leukemia and psoriasis |
| 07/25/2002 | US20020098582 Differentiated stem cells suitable for human therapy |
| 07/25/2002 | US20020098581 Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therefor |
| 07/25/2002 | US20020098580 MDM interacting protein and methods of use thereof |
| 07/25/2002 | US20020098550 Nucleotide sequences coding membrane protein for use in treatment and prevention of endotoxin shock, viral disease, immflammation and tumors |
| 07/25/2002 | US20020098540 Novel polypeptides, and nucleic acids encoding the same |
| 07/25/2002 | US20020098524 Screening peptide library for preferential proteins; obtain library, incubate with antitarget, separate unbound peptides, incubate unbound peptides with target binding protein, detect bound peptide complexes |
| 07/25/2002 | US20020098278 Coated implantable medical device |
| 07/25/2002 | US20020098252 Augmentation method for antitumor activity of substance containing amygdalin, composition containing augmented amygdalin contained substance, method for assessing antitumor efficacy of treatment for amygdalin contained substance and method for assessing antitumor substance containing amygdalin |
| 07/25/2002 | US20020098231 Antisense nucleotides; drug delivery; anticancer agents; gene expression inhibition |
| 07/25/2002 | US20020098206 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 07/25/2002 | US20020098205 Mostly comprising sodium metasilicate (pentahydrate) and shows nonspecific immunostimulating activity in plants and animals |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098197 Hla binding peptides and their uses |
| 07/25/2002 | US20020098192 Polyalkylene oxide-modified single chain polypeptides |
| 07/25/2002 | US20020098190 Delaying development of HMFG- and CEA- associated tumor by administering first antibody comprising light and heavy chain variable region sequences in SEQ ID NO:2 and NO:4, and second antibody comprising sequences in SEQ ID NO:6 and NO:8 |
| 07/25/2002 | US20020098177 17867, a novel human aminopeptidase |
| 07/25/2002 | US20020098176 Inhibition of tumor growth by a nematode anticoagulant protein |
| 07/25/2002 | US20020098170 Herpes simplex virus type 1 ( HSV-1)-derived vector for selectively inhibiting maligant cells and methods for its use to treat cancer and to express desired traits in maligant and non-miligant mammalian cells |
| 07/25/2002 | US20020098166 Genetically modified cells and their use in the prophylaxis or therapy of disorders |
| 07/25/2002 | US20020098164 Treatment of tumor metastases and cancer |
| 07/25/2002 | DE10102322A1 New disubstituted and trisubstituted benzene derivatives useful as coagulation inhibitors for the treatment of thromboembolic diseases |
| 07/25/2002 | DE10101522A1 Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| 07/25/2002 | DE10056059A1 Differenzierung auslösende Substanzen Differentiation-inducing substances |
| 07/25/2002 | CA2450929A1 Vegfr-3 binding peptides and their use for inhibiting angiogenesis |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |
| 07/25/2002 | CA2437038A1 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 07/25/2002 | CA2435363A1 New inhibitors against galectins |
| 07/25/2002 | CA2435322A1 Anticancer treatment using triptolide prodrugs |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2435077A1 Preparation for improved dietary utilisation |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434866A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | CA2434696A1 P27 prevents cellular migration |
| 07/25/2002 | CA2434490A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | CA2434350A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | CA2434300A1 Synthesis of temozolomide and analogs |
| 07/25/2002 | CA2434296A1 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | CA2434270A1 Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
| 07/25/2002 | CA2434099A1 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes |
| 07/25/2002 | CA2433862A1 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | CA2433316A1 Molecular antigen array |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2432041A1 Polynucleotides encoding human phosphatases |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2427643A1 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| 07/25/2002 | CA2426775A1 Thienopyrimidine-based inhibitors of the src family |
| 07/25/2002 | CA2406342A1 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225170A2 Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/24/2002 | EP1225169A1 Radiation-activated cytotoxin therapy |
| 07/24/2002 | EP1224943A1 Fibronectin as a tumor marker detected by phage antibodies |
| 07/24/2002 | EP1224941A2 Antithrombin III used in diseases caused by angiogenesis |
| 07/24/2002 | EP1224939A1 Interferon complex and medicinal use thereof |
| 07/24/2002 | EP1224931A1 Use of alkanoyloxymethyl esters for inhibiting histone deacetylase |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224302A2 Modified viral surface proteins which bind to cells of tumor vasculature |
| 07/24/2002 | EP1224288A2 Processed human chemokines phc-1 and phc-2 |
| 07/24/2002 | EP1224285A2 27 human secreted proteins |
| 07/24/2002 | EP1224282A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224274A1 Tumor necrosis factor related receptor, tr6 |
| 07/24/2002 | EP1224268A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 07/24/2002 | EP1224264A2 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 07/24/2002 | EP1224262A2 Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
| 07/24/2002 | EP1224261A1 C-myc antisense-treated hematopoietic stem cell composition and method |
| 07/24/2002 | EP1224222A2 Chemokine receptor |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224216A1 Mage-a1 peptides presented by hla class ii molecules |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224203A2 Antisense modulation of protein kinase c-theta expression |
| 07/24/2002 | EP1224202A1 Antisense modulation of integrin-linked kinase expression |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224192A1 Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer |
| 07/24/2002 | EP1224189A2 Condensed dihydroquinolinone derivatives for inhibiting mrp1 |
| 07/24/2002 | EP1224184A1 Novel limonoids for use particularly in the treatment of cancer and method for producing the same |
| 07/24/2002 | EP1224181A1 Substituted pyrroles as antiproliferative agents for the treatment of cancer |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/24/2002 | EP1224173A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 07/24/2002 | EP1224172A1 Drugs for the treatment of malignant tumours |
| 07/24/2002 | EP1224171A1 Beta disubstituted metalloprotease inhibitors |
| 07/24/2002 | EP1224170A1 6-position substituted indoline, production and use thereof as a medicament |
| 07/24/2002 | EP1224155A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 07/24/2002 | EP1224022A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 07/24/2002 | EP1223988A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 07/24/2002 | EP1223984A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 07/24/2002 | EP1223980A2 Use of csf-1 inhibitors |
| 07/24/2002 | EP1223978A2 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 07/24/2002 | EP1223977A2 Modified plant viruses and methods of use thereof |
| 07/24/2002 | EP1223976A1 Novel process for making human papillomavirus virus-like particles with improved properties |
| 07/24/2002 | EP1223973A2 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223965A2 Modulation of angiogenesis |
| 07/24/2002 | EP1223964A1 April receptor (bcma) and uses thereof |
| 07/24/2002 | EP1223959A2 Inhbition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 07/24/2002 | EP1223952A2 Methods for treatment of solid tumors and metastasis by gene therapy |
| 07/24/2002 | EP1223950A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 07/24/2002 | EP1223945A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |